Spruce Biosciences Receives Positive FDA Feedback on TA-ERT for Sanfilippo Syndrome Type B
Feb 18, 2026
Spruce Biosciences completed two Type B meetings with the FDA regarding tralesinidase alfa enzyme replacement therapy for Sanfilippo syndrome type B. The company now anticipates BLA submission in Q4 2026 to accommodate drug product process performance qualification requirements.